{"name":"Prothena Corporation","slug":"prothena","ticker":"PRTA","exchange":"NASDAQ","domain":"prothena.com","description":"Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a ne","hq":"Dublin, Ireland","founded":0,"employees":"67","ceo":"Gene Kinney, Ph.D.","sector":"Neuroscience / Amyloidosis","stockPrice":9.71,"stockChange":0.11,"stockChangePercent":1.15,"marketCap":"$508M","metrics":{"revenue":57940000,"revenueGrowth":1706.4,"grossMargin":-66.8,"rdSpend":134852000,"netIncome":-244092000,"cash":307531000,"dividendYield":0,"peRatio":-7.4,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Prothena Announces FDA Fast Track Designation for Birtamimab","summary":"Prothena Corporation plc (NASDAQ: PRTA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to birtamimab, the company's investigational antibody therapy for the treatment of AL amyloidosis.","drugName":"birtamimab","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"Prothena Reports Third Quarter 2023 Financial Results","summary":"Prothena Corporation plc (NASDAQ: PRTA) today reported its financial results for the third quarter ended September 30, 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Prothena Announces Collaboration with Biogen to Develop Therapies for Neurodegenerative Diseases","summary":"Prothena Corporation plc (NASDAQ: PRTA) today announced a collaboration with Biogen Inc. to develop therapies for neurodegenerative diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOVXNfMENmY0swQ1dDczBybnN5Q2JhVVF0Vko4NHhjeGNSZ2U1akdWVEdKZkt0SU9GaUZUWlRDblV0a1dCdE9saVVDQnhjaHVJdjAwbnZOMVN6aDRVYXVqTW9FeVktbXpJVHdFT3JlLVcxYlFDak04cDMwT0FrcTdrTFdOUnJvVmtzR251dTQ5RFgxcE8xNXMxQzhZUnladHF4eDdpMEd4Z2R5TTlKb1JwWEwtekdvTGJHY0NoSw?oc=5","date":"2026-03-31","type":"pipeline","source":"TradingView","summary":"Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease - TradingView","headline":"Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQUjhtbVRlRGlncHlFQWY5UjJlU2tjSVpIbzl6X2tQaWdhbFVxd3hXV05UM0hLVmtjSnRyU3JTZVd1QnVobUZybzhURnkzX29lTkFOS1BYNHd0UnZLRVRxYV9KSzJHN3lidWVUa3dWU2lSS2VzNDctQzVhWWdURWltZWJGUFFNUXVpR2Nkc29VUlRacWZScWpfZnVBNGdCMTAtZDdXRGpTR3I1UjFON3pPTXB4WTJlVGJyUkpB?oc=5","date":"2026-03-30","type":"regulatory","source":"TradingView","summary":"RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease - TradingView","headline":"RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-27","type":"earnings","source":"simplywall.st","summary":"When Can We Expect A Profit From Prothena Corporation plc (NASDAQ:PRTA)? - simplywall.st","headline":"When Can We Expect A Profit From Prothena Corporation plc (NASDAQ:PRTA)?","sentiment":"neutral"},{"date":"2026-02-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-27","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxNb1BYZmExSHlKU1VTYlBuRzFwQy1mYlRoVDBJaEI4UGdObWtMNlBVRHJLRWlBTll6U1ViRTN6ak40ZzdMa2dOSG5DdTZuZkh3QUVNMmFDaE5pQkFjd3Q5eEU1QWpMelBEc3BhYng5Z3BoNHQ5cEpwTTFxVmVnSHBnMDZiQktWbUZMZmgyS3UtdkFTSW0yeDR5TTRGZnc0YTlsYnd2R2Jub0t2bmJWZmUyZEdpZ1dDNTdGNDBDYm4zeGhKU2lwYXREV005VE1LZjl3QXk0?oc=5","date":"2025-11-12","type":"pipeline","source":"Sahm","summary":"Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker - Sahm","headline":"Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOU0JTRjlYZjZiNmg5TE9DaTRiV0Z6WXM5MkRSdG9Fa1JDcGpFc1BLT2EtUlZPams2R2J6bTdnb0NmU25GckVTQWZ0OVQxa1p6NzI2cWdMdzNLWVFicHBVVEF6M2swZzZMMjByRGg2a0JuaGpaSkpscWY2U1lsa21ic2hEVjdnRDA?oc=5","date":"2025-10-22","type":"pipeline","source":"Yahoo Finance","summary":"Prothena Corporation plc (PRTA): A Bull Case Theory - Yahoo Finance","headline":"Prothena Corporation plc (PRTA): A Bull Case Theory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOaUNadXd1YW5Lam5oYUg2WGxJY0pWVlNFME8zaTVkeTd0SllOd3k4bzZHNEk4ZEJucVdFYkw1Vk1FSjNtSV80UFlZX2ZBenJnSVduMm90TTJwQ2pXdU5oYWxKWVlubDN1SExCUHEtRHAzS0QxLThIYk5qNGRTS3Z6em1xWHVGQi05X3lJSTNLYmNTdTBIYWZpaklkOVVhU0lt?oc=5","date":"2025-06-18","type":"pipeline","source":"Business Wire","summary":"Prothena Announces Corporate Restructuring - Business Wire","headline":"Prothena Announces Corporate Restructuring","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-22","type":"pipeline","source":"simplywall.st","summary":"Why Investors Shouldn't Be Surprised By Prothena Corporation plc's (NASDAQ:PRTA) 27% Share Price Plunge - simplywall.st","headline":"Why Investors Shouldn't Be Surprised By Prothena Corporation plc's (NASDAQ:PRTA) 27% Share Price Plunge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNQmNSRERuQlptQkVYYU5qM3F4RkxlRklDdm56dWpsN0ZlUnFOVFJiVVdjU1BPUE9BZGpSeHhxZ3gxd0RjcWZkalFXRGNETHZ1aXN3QnM1QUxITHZVZ3NtNFBUbDZvWTEyenJyMGdXVXJRSENiYnBpZUdOdDJwX1hnN3NYR1N5UHFTeHZRMWp3cVlzT25TWTV5V1l5Xy1OeUJmeS1kQkxJRFVHcXVTZkhTNy15aDFPSTE0dTJnVjZJUXhheG9SUFBXWk52cw?oc=5","date":"2025-01-03","type":"pipeline","source":"Investing.com","summary":"Piper Sandler outlines biotech catalysts for 2025, highlights key stocks - Investing.com","headline":"Piper Sandler outlines biotech catalysts for 2025, highlights key stocks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNSldKZHZPVXZ4RF8tcmZHTTZLazZpQW42ZU5TaTlwaUVyYXFob3ZwZm04allwdFd0eklzbUNfU2NCWDNBSkZ1UDY2REc3Y2hJTWRmT0hUaTUzdTVQUld5N2NzVnV2UURvR3R3dGRLR3B1c0dlSVVaaXJEa1JXdTNSZ3NhNEU5cVdaWmtWczR4eWJiSU5JRlpKUVdOMzNOVV82dThTOXNoWVVuYUFOS1B3cU16X1lYdEZIZnhHTEVn?oc=5","date":"2024-09-27","type":"pipeline","source":"The Chronicle-Journal","summary":"Prothena Announces Leadership Team Updates - The Chronicle-Journal","headline":"Prothena Announces Leadership Team Updates - The Chronicle","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQMnhhMXRfdWJyWnQ2LWpoOFRMOTVZMFYwYTBHSzJ6dHgwejZLcDczNTJTSFh5VHpwSWdDYXVWWm9JZDNJOWdIeGhQRHBia0t2MHZTZjZ1NmJlclpnSTJuc0lyRHQ4UU5Bazk5M3NsM2hENVUwOWJmVUFIZEttcDNIRFhIbFdwcnZBYmc?oc=5","date":"2023-02-08","type":"deal","source":"Seeking Alpha","summary":"Prothena: I'm Not A Buyer At A $3 Billion Valuation (PRTA) - Seeking Alpha","headline":"Prothena: I'm Not A Buyer At A $3 Billion Valuation (PRTA)","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Ionis Pharmaceuticals","Alnylam Pharmaceuticals"],"therapeuticFocus":["Amyloidosis","Neurodegenerative Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":814000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":814000,"period":"2019-12-31"},{"value":205000,"period":"2019-09-30"},{"value":167000,"period":"2019-06-30"},{"value":186000,"period":"2019-03-31"},{"value":955000,"period":"2018-12-31"},{"value":255000,"period":"2018-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":134852000,"rdSpendHistory":[{"period":"2025-12-31","value":134852000},{"period":"2024-12-31","value":222519000},{"period":"2023-12-31","value":220571000},{"period":"2022-12-31","value":135562000}],"sgaSpend":59392000,"operatingIncome":-184560000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-184560000},{"period":"2024-12-31","value":-154561000},{"period":"2023-12-31","value":-191036000},{"period":"2022-12-31","value":-131557000}],"netIncome":-244092000,"netIncomeHistory":[{"period":"2025-12-31","value":-244092000},{"period":"2024-12-31","value":-122310000},{"period":"2023-12-31","value":-147028000},{"period":"2022-12-31","value":-116949000}],"eps":-4.53,"epsHistory":[{"period":"2025-12-31","value":-4.53},{"period":"2024-12-31","value":-2.27},{"period":"2023-12-31","value":-2.76},{"period":"2022-12-31","value":-2.47}],"cash":307531000,"cashHistory":[{"period":"2025-12-31","value":307531000},{"period":"2024-12-31","value":471388000},{"period":"2023-12-31","value":618830000},{"period":"2022-12-31","value":710406000}],"totalAssets":326804000,"totalLiabilities":46330000,"totalDebt":8373000,"equity":280474000,"operatingCashflow":-163580000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-163580000},{"period":"2024-12-31","value":-150050000},{"period":"2023-12-31","value":-133906000},{"period":"2022-12-31","value":-108821000}],"capex":-138000,"capexHistory":[{"period":"2025-12-31","value":-138000},{"period":"2024-12-31","value":-298000},{"period":"2023-12-31","value":-2810000},{"period":"2022-12-31","value":-464000}],"freeCashflow":-163718000,"dividendsPaid":null,"buybacks":-139000,"employees":67,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":12646000,"ebit":-27211000,"ebitda":-26993000,"period":"2025-12-31","revenue":21000,"epsBasic":-0.4,"netIncome":-21589000,"rdExpense":14586000,"epsDiluted":-0.4,"grossProfit":null,"operatingIncome":-27211000},{"sga":13238000,"ebit":-39761000,"ebitda":-39532000,"period":"2025-09-30","revenue":2415000,"epsBasic":-0.68,"netIncome":-36541000,"rdExpense":28938000,"epsDiluted":-0.68,"grossProfit":null,"operatingIncome":-39761000},{"sga":15910000,"ebit":-52007000,"ebitda":-51782000,"period":"2025-06-30","revenue":4420000,"epsBasic":-2.34,"netIncome":-125767000,"rdExpense":40517000,"epsDiluted":-2.34,"grossProfit":null,"operatingIncome":-52007000},{"sga":17598000,"ebit":-65581000,"ebitda":-65358000,"period":"2025-03-31","revenue":2828000,"epsBasic":-1.12,"netIncome":-60195000,"rdExpense":50811000,"epsDiluted":-1.12,"grossProfit":null,"operatingIncome":-65581000},{"sga":16848000,"ebit":-64897000,"ebitda":-64676000,"period":"2024-12-31","revenue":2123000,"epsBasic":-1.08,"netIncome":-57956000,"rdExpense":50172000,"epsDiluted":-1.08,"grossProfit":null,"operatingIncome":-64897000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":9.71,"previousClose":9.6,"fiftyTwoWeekHigh":11.8,"fiftyTwoWeekLow":4.32,"fiftyTwoWeekRange":"4.32 - 11.8","fiftyDayAverage":10.04,"twoHundredDayAverage":9.48,"beta":-0.23,"enterpriseValue":180783072,"forwardPE":-7.4,"priceToBook":1.86,"priceToSales":8.77,"enterpriseToRevenue":3.12,"enterpriseToEbitda":-1.96,"pegRatio":0,"ebitda":-92332000,"ebitdaMargin":-159.4,"freeCashflow":-31584500,"operatingCashflow":-81340000,"totalDebt":7654000,"debtToEquity":2.4,"currentRatio":10.43,"returnOnAssets":-13.8,"returnOnEquity":-40.3,"analystRating":"2.5 - Buy","recommendationKey":"buy","numberOfAnalysts":5,"targetMeanPrice":21.4,"targetHighPrice":36,"targetLowPrice":8,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":19.9,"institutionHeldPercent":92.4,"sharesOutstanding":52353237,"floatShares":38560253,"sharesShort":6871465,"shortRatio":15.99,"shortPercentOfFloat":13.1,"epsTrailing":-2.81,"epsForward":-1.31,"revenuePerShare":1.08,"bookValue":5.21,"officers":[{"age":56,"name":"Dr. Gene G. Kinney Ph.D.","title":"President, CEO & Director"},{"age":51,"name":"Mr. Tran B. Nguyen M.B.A.","title":"Chief Financial Officer"},{"age":50,"name":"Mr. Brandon S. Smith","title":"Chief Operating Officer"},{"age":52,"name":"Dr. Wagner M. Zago Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Dr. Chad H. Swanson Ph.D.","title":"Chief Development Officer"},{"age":62,"name":"Ms. Karin L. Walker CPA","title":"Chief Accounting Officer & Controller"},{"age":null,"name":"Mr. Mark C. Johnson C.F.A.","title":"Vice President of Investor Relations"},{"age":59,"name":"Mr. Michael J. Malecek","title":"Chief Legal Officer & Company Secretary"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.prothena.com","phone":"353 1 236 2500"}}